ScinoPharm begins Viibryd production; announces facility expansion
The drug, which was recently approved by the US FDA, is intended used to treat adults with major depressive disorder (MDD). Clinical Data claim use of Viibryd results in patients experiencing fewer of the side effects commonly associated with other antidepressants.
Dr Jo Shen, President and CEO of ScinoPharm expressed the Taiwanese company's pride at its “fruitful partnership” with Clinical Data.
“Beginning from process research through timely development and optimisation of long and complicated synthetic processes, we have established a win-win partnership,” she said.
ScinoPharm are also set to expand their contract research and manufacturing (CRAM) services through a new facility in Changshu, China.
The company expects the plant to become operational in the third quarter of 2011 in the hope it will increase R&D and production capabilities, thus boosting their business prospects in the burgeoning Asian pharmaceuticals market.
